Evaluation of HER2DX Assay on Treatment Decisions in Patients With Early Stage HER2+ Breast Cancer: the HER2BREASTDX
This is not medical advice. AI-assisted translation — inaccuracies may occur. Always verify the original and consult your oncologist before taking any steps.
About the trial
To prospectively evaluate the impact of HER2DX on the decision-making processes of the treating physicians and especially among the routine multidisciplinary tumour board, in defining type and setting of systemic therapy administration in patients with stage I-III HER2+ BC, and the degree of clinician's confidence in the treatment recommendation.
Original English text from ClinicalTrials.gov
Who can (and can't) join
✓ Qualifies
- •Wiek 18 lat lub więcej
- •Rak piersi potwierdzony badaniem histologicznym z cechą HER2+
- •Rak piersi w stadium I-III bez przerzutów do odległych organów
- •Kwalifikacja do leczenia przedoperacyjnego lub pooperacyjnego oraz zabiegu chirurgicznego (z ewentualną radioterapią)
- •Podpisana świadoma zgoda pacjenta na uczestnictwo w badaniu
✗ Disqualifies
- •Rak piersi bez cechy HER2+
- •Rak piersi w stadium IV
- •Brak świadomej zgody pacjenta lub niezdolność do uczestnictwa w badaniu
Simplified criteria — AI translation
Trial details
- Minimum age
- 18 Years
- Last updated (source)
- February 11, 2026
- Sex
- No restrictions
Therapies / drugs in trial
Locations (1)
Istituto Europeo di Oncologia
Milan, Italy
Trial contact
Paola Zagami
Contact information from ClinicalTrials.gov. Contact in English.
Share this trial
Data from ClinicalTrials.gov. AI-assisted translation, last sync: 7/1/2026.
You can help another person
We fund the Radar, this site, and the development of our Grosz dla Życia fundraising platform from donations and our own resources. Every contribution, even a small one, really helps.